## HCA: HCA Healthcare, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.2% below STRENGTH zone (3.0-6.0%); PEG 1.29 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($447.23)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 2, Bearish: 2)

**1. Morgan Stanley downgrades HCA Healthcare stock on peak valuation concerns**
- Source: Investing.com India | 20251215T090207 | Bearish | Relevance: 100%
- Morgan Stanley downgraded HCA Healthcare Inc (NYSE:HCA) from Equalweight to Underweight, setting a price target of $425.00 due to significant stock outperformance and peak valuation multiples. Despite the company's strong execution and shareholder-friendly capital allocation, including substantial share buybacks, the firm warns of potential deceleration in HCA's stock as tailwinds from healthcare policies are expected to ease. HCA's stock has risen 62% year-to-date in 2025, but trades at a high P/E ratio of 18.7 relative to its near-term earnings growth potential.

**2. Ten-Year Tally: HCA Healthcare Stock Delivers $43 Bil Gain**
- Source: Trefis | 20251217T061509 | Bullish | Relevance: 100%
- This article from Trefis discusses the ten-year performance of HCA Healthcare stock, highlighting a $43 billion gain. It appears to be an introductory piece to a detailed financial analysis or model on their platform.

**3. Why HCA Healthcare (HCA) is a Top Growth Stock for the Long-Term**
- Source: www.sharewise.com | 20251216T214257 | Bullish | Relevance: 100%
- HCA Healthcare (HCA) is identified as a top growth stock due to its strong financial health and promising future outlook, earning an "A" Growth Style Score and "A" VGM Score from Zacks. The company, a leading operator of acute care hospitals, is projected to see a 24.7% year-over-year earnings growth for the current fiscal year, with analysts revising estimates upwards. Investors looking for companies with high growth potential should consider HCA, particularly given its Zacks Rank #3 (Hold) combined with excellent Style Scores.

**4. HCA Healthcare Hits A High But Morgan Stanley Turns Cautious**
- Source: Finimize | 20251215T160841 | Somewhat-Bearish | Relevance: 100%
- Morgan Stanley has downgraded HCA Healthcare to 'underweight', causing a 2% drop in its share price. The downgrade comes after years of HCA outperforming the market, with analysts citing stretched valuations and the fading impact of post-pandemic patient surges and ACA enrollments as key reasons. This signals a potential shift in sentiment for the healthcare sector as a whole, which may face increased scrutiny.

**5. HCA Downgraded by Morgan Stanley with Price Target Maintained |**
- Source: GuruFocus | 20251215T135017 | Somewhat-Bearish | Relevance: 100%
- Morgan Stanley has downgraded HCA Healthcare (HCA) from 'Equal-Weight' to 'Underweight', although the price target of $425.00 USD was maintained. This decision follows various analyst ratings, with other firms maintaining 'Buy' or 'Outperform' ratings and increasing price targets for HCA. Despite the downgrade, the average analyst target price is $479.92, suggesting a minor downside, while GuruFocus estimates a 9.69% downside based on its GF Value.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Morgan Stanley | $425 | $425 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Morgan Stanley | down | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($3.12M) |
| Sells | 4 ($14.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 29.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 6.5% (-3.8%)
- Blackrock Inc.: 5.5% (-3.7%)
- Sanders Capital, LLC: 4.7% (-3.9%)
- State Street Corpora: 3.3% (-5.9%)
- JPMORGAN CHASE & CO: 2.6% (+82.2%)

### Key Risks

1. Heavy insider selling: $15M sold (4 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +3.1% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.29 suggests fair value with growth premium. Forward P/E 15.8x stretched relative to 8% growth. Quality metrics strong (ROE 136%, ROA 12%). Balance sheet: $3.1B free cash flow. Insider selling cluster ($14.8M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $110.4B |
| Beta | 1.37 |
| 52W Range | $289.98 - $520.00 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.29 |
| Forward P/E | 15.8 |
| Current P/E | 17.0 |
| YoY Growth | 7.6% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -1.9% to 1.2% (+3.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.8pp (needs >3.0% for momentum thesis). MRS_5 at 0.9% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.20x) but short-term weakness (below SMA20). MACD histogram bearish (-4.26), momentum weakening. RSI neutral at 46. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.21% (CS: 37) | Neutral |
| RSI_14 | 45.6 | Neutral |
| MACD Histogram | -4.26 | Bearish |
| vs SMA20 | 0.965x | Below |
| vs SMA50 | 1.012x | Above |
| vs SMA200 | 1.197x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $471.91
- **Stop Loss:** $447.23 (5.2% risk)
- **Target:** $496.59 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 43
- **Position Value:** $20,292.13
- **Portfolio %:** 20.29%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-01-23 (Est: $7.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.73 | $6.96 | +21.6% |
| 2025Q2 | $6.32 | $6.84 | +8.2% |
| 2025Q1 | $5.75 | $6.45 | +12.1% |
| 2024Q4 | $6.14 | $6.22 | +1.2% |

---
*RULE-based L3 | 2026-01-07 01:40 | MRS_10*